IL195971A0 - Use of defibrotide for the inhibition of heparanase - Google Patents

Use of defibrotide for the inhibition of heparanase

Info

Publication number
IL195971A0
IL195971A0 IL195971A IL19597108A IL195971A0 IL 195971 A0 IL195971 A0 IL 195971A0 IL 195971 A IL195971 A IL 195971A IL 19597108 A IL19597108 A IL 19597108A IL 195971 A0 IL195971 A0 IL 195971A0
Authority
IL
Israel
Prior art keywords
defibrotide
heparanase
inhibition
Prior art date
Application number
IL195971A
Other languages
English (en)
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Publication of IL195971A0 publication Critical patent/IL195971A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL195971A 2006-06-27 2008-12-16 Use of defibrotide for the inhibition of heparanase IL195971A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06425436A EP1872787A1 (en) 2006-06-27 2006-06-27 Use of defibrotide for the inhibition of heparanase
PCT/EP2007/054633 WO2008000549A1 (en) 2006-06-27 2007-05-14 Use of defibrotide for the inhibition of heparanase

Publications (1)

Publication Number Publication Date
IL195971A0 true IL195971A0 (en) 2009-09-01

Family

ID=37496823

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195971A IL195971A0 (en) 2006-06-27 2008-12-16 Use of defibrotide for the inhibition of heparanase

Country Status (6)

Country Link
US (2) US20090131362A1 (enExample)
EP (2) EP1872787A1 (enExample)
JP (1) JP2009541409A (enExample)
CA (1) CA2655522A1 (enExample)
IL (1) IL195971A0 (enExample)
WO (1) WO2008000549A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
JP6069209B2 (ja) 2010-11-12 2017-02-01 ジェンティウム ソシエタ ア レスポンサビリタ リミタータ 移植片対宿主病（ｇｖｈｄ）の予防および／または治療に使用するためのデフィブロタイド
JP6198821B2 (ja) 2012-06-22 2017-09-20 ゲンチウム エス．アール．エル． デフィブロチドの生物学的活性を決定する為の、ユーグロブリンに基づく方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
MX2020001337A (es) 2017-08-03 2020-09-09 Jazz Pharmaceuticals Ireland Ltd Formulaciones que comprenden un acido nucleico en una alta concentracion.
MX2020010689A (es) 2018-04-12 2021-01-20 Jazz Pharmaceuticals Inc Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
WO2021174039A1 (en) 2020-02-28 2021-09-02 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
WO2022234101A1 (en) 2021-05-06 2022-11-10 Jazz Pharmaceuticals Ireland Limited Defibrotide for the treatment and prevention of acute respiratory distress syndrome

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) * 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170215B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) * 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) * 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
US4753221A (en) * 1986-10-22 1988-06-28 Intravascular Surgical Instruments, Inc. Blood pumping catheter and method of use
IT1231509B (it) * 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
FR2654271B1 (fr) * 1989-11-06 1992-01-24 Moving Magnet Tech Actionneur electromagnetique monophase angulaire.
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5624912A (en) * 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
DE69928778T2 (de) * 1999-06-08 2006-07-06 Gentium S.P.A., Villa Guardia Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln
US20070037144A1 (en) * 2000-10-20 2007-02-15 Jay Wohlgemuth Leukocyte expression profiling
SE0003912D0 (sv) * 2000-10-24 2000-10-24 Abb Ab Industrirobot
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2003027313A2 (en) * 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1325962A1 (en) * 2001-12-17 2003-07-09 Gentium S.p.A. A method for determining the biological activity of defibrotide
KR100509057B1 (ko) * 2002-10-23 2005-08-18 엘지전자 주식회사 진공청소기용 흡입노즐
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.

Also Published As

Publication number Publication date
US20090131362A1 (en) 2009-05-21
JP2009541409A (ja) 2009-11-26
WO2008000549A1 (en) 2008-01-03
CA2655522A1 (en) 2008-01-03
EP2035013A1 (en) 2009-03-18
EP1872787A1 (en) 2008-01-02
US20150196580A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
IL195971A0 (en) Use of defibrotide for the inhibition of heparanase
ZA200705783B (en) Amino-imidazolones for the inhibition of ß-secretase
IL200603A0 (en) Inhibitors of the hedgehog pathway
ZA200808253B (en) Inhibition of alpha-synuclein toxicity
PT2397142T (pt) Utilizações de inibidores da dpp iv
ZA200804932B (en) Compounds for the inhibition of integrins and use thereof
ZA201001868B (en) Inhibition of angiogenesis
GB0912562D0 (en) LXR-antagonists for the prevention, reduction or inhibition of scarring
IL218617A (en) Derivatives of pyridinylimidazolone for inhibition of 3pi kinases
GB0719997D0 (en) Portease Inhibition
EP2048997A4 (en) TOWEL
GB0622084D0 (en) Inhibitors of HSP90
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB2447028B (en) Inhibition of corrosion of structures
EP2039342A4 (en) MEANS FOR MAINTAINING THE HARDENING TISSUE STRUCTURE
GB0605685D0 (en) Inhibition of tumour growth
GB0611558D0 (en) Towel
EP2124987A4 (en) METHOD OF USE OF EPSILON HEMMER COMPOUNDS FOR PAIN LIFTING
PL380561A1 (pl) Sposób otrzymywania pochodnych antracyklin
GB0603522D0 (en) Kinase inhibition
IL193025A0 (en) Crystalline forms of ciclesonide
ZA201004090B (en) Methods for the inhibition of scarring
IL197485A0 (en) Use of vitamin d compounds for the prevention of adhesions
GB0602857D0 (en) The treatment of sialorrhoea